Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary Nitric Oxide (NO) Generator and Delivery System platform (LungFit™) that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.
LungFit™ can generate up to 400 parts per million (ppm) of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose.
The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care.
Beyond Air’s lead product in development is LungFit PH™. LungFit PH™ is a ventilator-compatible NO Generator and Delivery System that is a cylinder-free, phasic flow nitric oxide delivery system and has been designated as a medical device by the US Food and Drug Administration (FDA). The device can generate NO on demand for delivery to the lungs at concentrations ranging from 1 part per million (ppm) to 80 ppm. The elimination of the need for large, high-pressure cylinders for NO is a significant advantage in the hospital setting by greatly reducing inventory and storage requirements and improving overall safety with the elimination of NO2 purging steps, among other benefits.
Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis (LungFit BRO™) and severe lung infections such as non-tuberculous mycobacteria (LungFit NTM™).
AIT Therapeutics, commencing June 26, 2019 is named Beyond Air™.
AIT Therapeutics Inc. completed an uplisting to the NASDAQ stock exchange and started trading on May 7, 2019 under the symbol AITB.
Beyond Air Inc. expects to trade under the new symbol, XAIR, starting July 15, 2019
*LungFit™ is not an approved name for the product and may not be the final name submitted for approval.